stars 1 stars 2 stars 3

Axio is a deep-science medical technology company with extensive expertise in biomaterials based medical devices for pre-hospital, intra-operative and post-operative clinical needs. Our focus is on devices for management of trauma, surgical and chronic wounds. Our flagship product, Axiostat, is a patented, clinically validated haemostat that stops moderate to severe bleeding instantly in surgeries and in pre-hospital trauma. Axiostat is USFDA 510(k) cleared and is also European CE approved. In Advanced Wound Care range, Axio has launched the next-generation MaxioCel wound dressing. MaxioCel is designed to heal patients suffering from acute and chronic wounds (diabetic foot ulcers, pressure ulcers, burns, bed sores, cavity wounds and surgical site infections) by effectively managing exudates, pain reduction and scar less healing. All Axio products are manufactured in state-of-the-art ISO 13485 and GMP certified facility.

Axio Biosolutions Questions

The Axio Biosolutions annual revenue was $25.1 million in 2026.

Leo Mavely is the Founder and CEO of Axio Biosolutions.

98 people are employed at Axio Biosolutions.

Axio Biosolutions is based in Ahmedabad, Gujarat.

The NAICS codes for Axio Biosolutions are [339, 33].

The SIC codes for Axio Biosolutions are [384, 38].

Top Axio Biosolutions Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users